Streetbeat News

INBS

Intelligent Bio Solutions Inc.

https://gbs.inc

Industry

Medical - Diagnostics & Research

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Open

1.82

Mkt cap

6.9M

Volume

180K

High

1.82

P/E Ratio

-0.26

52-wk high

11.70

Low

1.56

Div yield

N/A

52-wk low

1.00

In Friday's pre-market session, health care stocks showed significant movement. Ainos, Psyence Biomedical, and Mira Pharmaceuticals were among the top gainers, with Ainos leading at a 144.6% increase. On the downside, Amylyx Pharma experienced a significant drop of 81.5%. Other notable movers include Viracta Therapeutics with a 17.18% increase following their Q4 earnings report, and ALX Oncology Holdings, which fell 10.41% also after their Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 1:09 pm

Intelligent Bio Solutions (NYSE:INBS) has seen a 35.31% decrease in short interest, now at 140,000 shares or 6.54% of float. This compares to a peer average of 1.72%. Short interest can indicate market sentiment, and a decrease may suggest a more bullish outlook.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 2:30 pm

Intelligent Bio Solutions Inc. (INBS) partners with Cliantha Research for a pharmacokinetic study as part of its FDA 510(k) clinical study plan. The study aims to compare opiate levels in fingerprint sweat against traditional specimens, using INBS' Intelligent Fingerprinting Drug Screening System. This marks a significant step in INBS' journey towards FDA approval and U.S. market entry. The FDA has provisionally classified the screening cartridge as a Class II device, requiring 510(k) submission and clearance. The study, starting in May 2024, seeks to validate fingerprint sweat as a reliable testing method for opiates.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 1:35 pm

Intelligent Bio Solutions (NYSE:INBS) has seen a significant increase in short interest, with the short percent of float rising 165.35% to 10.11% of all shares available for trading. This increase indicates a more bearish market sentiment towards INBS, although it doesn't necessarily predict a near-term price fall. Compared to its peers, INBS has a higher short interest, with the average for its peer group at 2.99%.

Portfolio Pulse from Benzinga Insights

February 19, 2024 | 6:45 pm

Big Lots, Inc. shares plummeted by 31.3% after reporting disappointing preliminary Q4 results and a downgrade by Loop Capital. Other stocks showed significant movement, with notable gainers including Millennium Group International Holdings Limited, Beamr Imaging Ltd., and DIH Holdings US, Inc. Losers included AN2 Therapeutics, Inc., AirTouch Communications, Inc., and TOP Financial Group Limited.

Portfolio Pulse from Avi Kapoor

February 12, 2024 | 6:07 pm

Health care stocks experienced significant movements in Monday's intraday session. Renalytix saw a dramatic increase of 490.4%, while AN2 Therapeutics faced a sharp decline of 75%. Other notable movers include Regencell Bioscience and Genenta Science with substantial gains, and InVivo Therapeutics and TC BioPharm with significant losses.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 5:31 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. SeaStar Medical Holding (ICU) led the gainers with a 27.9% increase, while AN2 Therapeutics (ANTX) experienced the largest drop among the losers, declining by 69%. Other notable movers included Aesthetic Medical Intl (AIH), Virios Therapeutics (VIRI), and Exscientia (EXAI) with substantial gains, and Larimar Therapeutics (LRMR) and Invivyd (IVVD) with notable losses.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 1:06 pm

Amtech Systems, Inc. (NASDAQ:ASYS) shares rose by 7.6% in pre-market trading after reporting Q1 results that exceeded expectations, with an adjusted loss of 4 cents per share against estimates of a 26 cents loss and sales of $24.92 million against expected $22.25 million. Other stocks also showed significant movement in pre-market trading, with notable gainers including Millennium Group International Holdings Limited (NASDAQ:MGIH) and DIH Holdings US, Inc. (NASDAQ:DHAI), and losers like Intelligent Bio Solutions Inc. (NASDAQ:INBS) and Better Choice Company Inc. (NYSE:BTTR).

Portfolio Pulse from Avi Kapoor

February 12, 2024 | 10:39 am

In Friday's after-market session, several health care stocks showed significant movement. Notably, Singular Genomics Systems, Vaccinex, and Celularity experienced upward movements, while Intelligent Bio Solutions, Perspective Therapeutics, and NanoString Technologies were among the losers. The changes in stock prices reflect varying market capitalizations, highlighting the dynamic nature of the health care sector in the stock market.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 9:31 pm

U.S. stocks showed mixed performance with the Nasdaq Composite rising by 1.26% and the S&P 500 gaining 0.55%, while the Dow slightly declined. Newell Brands Inc. reported higher than expected Q4 sales but forecasted a significant sales decline for FY24, impacting its stock. In other news, Intelligent Bio Solutions, Masonite International, and Cloudflare saw significant stock price increases following positive financial results and acquisition news. Conversely, The Children's Place, Synlogic, and EMCORE Corporation experienced substantial drops in their stock prices due to disappointing financial updates and operational changes.

Portfolio Pulse from Avi Kapoor

February 09, 2024 | 7:38 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.